Cell therapy (CAR-T) · Kills target cells, directed at NKG2D ligands · developed by CytoMed Therapeutics Pte
CTM-N2D is an allogeneic cell therapy made from healthy donor gamma delta T cells expanded ex vivo and engineered by mRNA electroporation with chimeric antigen receptors targeting NKG2D ligands. The cells are infused into cancer patients, with the aim of killing NKG2D ligand-expressing cancer cells. It is studied in cancer, malignancy and relapsed or refractory cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05302037 | Phase 1 | Cancer | Recruiting | GDTC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CancerMalignancyRefractory CancerRelapsed Cancer
Updated Oct 11, 2026. Something wrong or missing? Report it on the GDTC page.
See GDTC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GDTC catalysts and pipeline →